
FOR DEBATE

Coxiella burnetii and milk pasteurization: an early application of the precautionary principle?

O. CERF¹* AND R. CONDRON²

¹ Department of Animal Productions and Public Health, Alfort Veterinary School, Maisons-Alfort, France

² Dairy Australia, Melbourne, Australia

(Accepted 19 December 2005, first published online 22 February 2006)

SUMMARY

Stringency of milk pasteurization has been established on requirements for *Coxiella burnetii* as being the most heat-resistant organisms of public health significance. This paper discusses the estimation of the efficiency of pasteurization time/temperature combinations as required in regulations for food safety. Epidemiological studies have been interpreted as *C. burnetii* being a significant pathogen causing clinical disease through ingestion of milk. The paper examines the evidence and challenges the designation of *C. burnetii* as a foodborne pathogen. Consequently it questions the need for pasteurization parameters to be established on its heat resistance characteristics.

INTRODUCTION

Milk pasteurization was introduced to prevent the oral transmission of tuberculosis, brucellosis, and other milk-borne infectious diseases. Early in the twentieth century, it was established that the cells of the tubercle bacillus were the most heat-resistant vegetative bacterial cells in milk. Therefore, the first recommendations for time and temperature combinations for pasteurization were established on this basis. However, pasteurization of milk is defined by the Codex alimentarius Committee for Food Hygiene [1] as ‘a microbiocidal heat treatment aimed at reducing the number of any pathogenic microorganisms in milk and liquid milk products, if present, to a level at which they do not constitute a significant health hazard. Pasteurization conditions are designed to effectively destroy the organisms *Mycobacterium tuberculosis* and *Coxiella burnetii*’.

Thus the international definition points to the need for the destruction of *Coxiella burnetii* to protect the health of milk consumers.

C. burnetii is the cause of Q fever, recognized in 1935 as an occupational disease of workers in abattoirs in Australia and as a tick-transmitted disease in the United States [2]. After the Second World War, a high prevalence of Q fever and serological conversion was observed among the population in Europe and North America, in regions where raw milk and raw milk products were commonly consumed [3, 4]. There was a consensus that milk should not be consumed raw and, therefore, milk pasteurization was recommended. Studies were conducted in several countries to check the efficiency of heat against *C. burnetii* [3, 5–9]. Eventually time-temperature conditions for pasteurization published by US researchers in 1957 [10–12] became the international standard.

In the first part of this paper, we will indicate how these researchers used a safety factor, and will show that the recommended heating treatment not only provides at least 4·7 decimal reductions or ‘log kills’

* Author for correspondence: Professor O. Cerf, École nationale vétérinaire d’Alfort, 7 avenue du Général de Gaulle, F-94700 Maisons-Alfort, France.
(Email: ocerf@vet-alfort.fr)

Table. Number of decimal reductions (log kills) of *C. burnetii* demonstrated experimentally, and values calculated for internationally recommended pasteurization time/temperature combinations, assuming a linear survival curve. Calculations were done with $z=4.34\text{ }^{\circ}\text{C}$

Temp. (F)	Temp. (°C)	Decimal reduction time, D	Min. time of destruction plus 2 s.d.*	Corresponding number of decimal reductions	Combinations recommended by the authors	Corresponding number of decimal reductions	Presently recommended combinations	Corresponding number of decimal reductions
145	62.8	4.14 min	25.42 min	6.1	30 min	7.2		
	63	3.72 min					30 min	8.1
161	71.7	2.21 s	15.4 s	6.9	15 s	6.8		
	72	1.88 s					15 s	7.9

* s.d., Standard deviation.

(rather than 5 as usually reported), but plausibly even more. In the second part we will question if Q fever is a foodborne disease and if pasteurization is scientifically justified for the prevention of Q fever.

Heat resistance of *C. burnetii*

A number of studies conducted to measure the heat resistance of *C. burnetii* did not lead to any convincing conclusion related to the efficacy of time-temperature combinations used in pasteurizers [3, 5-9]. Enright *et al.* [11, 12] put an end to this by publishing undisputed results validated through infection studies in guinea pigs by intraperitoneal inoculation. Since the appearance of specific complement-fixing antibody was significantly induced by killed *C. burnetii*, the authors demonstrated the presence of infective viable microbial cells by two consecutive passages on guinea pigs. They used whole raw milk from an experimentally infected cow containing 10^5 infecting doses in 2 ml (5×10^4 infective doses/ml) and heated in the laboratory at temperatures from 60.6 to 66.1 °C for different lengths of time.

For the shortest heating times, viable cells were still present. For the longest heating times, no viable cells could be found. Linear regressions of $\log_{10}(\text{time})$ against temperature were calculated to determine two lines:

- the line A below which vials were still positive (containing at least one surviving cell);
- the line B over which no vial contained survivors (corresponding to the ‘minimum time of destruction’ according to the authors).

Positive as well as negative vials could be found between lines A and B.

A second series of experiments conducted by a regular commercial pasteurization plant from 68.1 to 72.8 °C confirmed the validity of the first series.

The authors based their recommendations for pasteurization conditions by adding two standard deviations or 97.7% confidence interval to the minimum times of destruction estimated by the regression B. They finally recommended two time-temperature combinations that have subsequently been universally recognized: 30 min at 62.8 °C (145 F) or 15 s at 71.7 °C (161 F).

The influence of temperature is, therefore, given by $z=4.34\text{ }^{\circ}\text{C}$. These recommendations were then simplified as follows [1, 13]: 30 min at 63 °C or 15 s at 72 °C, thus providing an extra safety margin. Assuming the survival curves are straight lines, this would achieve eight decimal reductions.

If, for a given temperature $\log_{10}(a)$ is the ordinate of line A, and $\log_{10}(b)$ the ordinate of line B, then the most probable time t for which there is one survivor per vial is [14]:

$$\log_{10} t = 0.63 (\log_{10} b - \log_{10} a) + \log_{10} a$$

and the decimal reduction time is calculated with [14]:

$$D = t / \log_{10}(N),$$

where N is the initial number of microbial cells per vial.

The experimental data of Enright *et al.* [11] are reported in the Table together with calculated D values and numbers of decimal reductions corresponding to recommended treatments.

The experimental work of Enright *et al.* [11, 12] was performed carefully. It was the first study regarding *C. burnetii* where the results were modelled using statistical regression, and where a safety margin was

used. However, the paper was not clear as to the origin of the *C. burnetii* cells subjected to heating: whether they were from one or several animals; and whether a single strain or a mixture of strains was used? The shape of survival curves was not studied, and it was not checked if the curve was linear or biphasic, i.e. having a second part or 'tail' indicative of a slower killing rate; therefore, the addition of two standard deviations by Enright *et al.* [11] did not guarantee a larger killing effect. While there is no certainty about the actual number of decimal reductions, one can nevertheless reasonably assume that, for the studied strain(s), pasteurization achieved between 4.7 [i.e. $\log_{10}(5 \times 10^4)$] and 8 decimal reductions of *C. burnetii*.

Transmission of Q fever to people

It is well documented that *C. burnetii* is transmitted to man from infected wild or domesticated mammals, including farm animals and pets, by inhalation and by bites of haematophagous arthropods. The disease affects mostly farmers, veterinarians, researchers, abattoir workers and persons exposed to aerosols in dwellings situated down wind, or being in the vicinity of infected herds [15–49]. All outbreaks and sporadic cases reported for the last 50 years in Australia, France, Germany, Italy, and the United States were attributed to inhalation and sometimes to arthropod bites [23, 24, 26, 27, 31, 34, 36, 39, 47, 50–55]. No information is given of the infective dose.

In his comprehensive review, Wegener [3] noted the widespread opinion at that time: 'Milk is the most significant source among products of animal origin. Personnel in dairies and their families with the greatest use of raw milk are heavily infected in the regions with Q fever problems in North America and Italy.' This opinion on foodborne transmission was based on a survey in the United States where 10.7% of people consuming raw milk had a positive serological test, compared to 0.7% among non-exposed people. Other authors used the same argument on the basis of observations in England [4, 17, 56] and in other countries [18, 19, 25, 57–60]. Nevertheless several reports mentioned the oral route as possible but infrequent, circumstantial, or needing a very high dose [15, 33, 44, 61–63]. According to Enright *et al.* [11], milk of naturally infected cows contained the following numbers of guinea pig infective doses (ID) per millilitre: 1 (5 animals), 10 (5 animals), 100

(5 animals) or 1000 (3 animals), while the milk of an experimentally infected cow contained 10 000 guinea pig ID/ml. These microbiological loads should be compared to those of inhaled air around infected animals or herds. However, we could not find any indication of these.

A few publications that reported a correct epidemiological approach did confirm that seroconversion indicated infection, but not the clinical disease. Fishbein *et al.* [18] reported a significant association between seropositivity and drinking non-pasteurized milk products whether people were in contact with goats or not, but the article did not provide information about clinical disease. Benson *et al.* [62] indicated that 35% of prisoners drinking infected milk had a positive serological test against 4% in a non-exposed control group; yet the authors emphasized that no manifestations of disease were recorded. Hatchette *et al.* studied an outbreak affecting goats in Newfoundland (Canada):

Risk factors associated with human infection [based on people with serological conversion, but where infection was not confirmed and no indication was given in the paper about manifestation of disease] on univariate analysis included being a farmer, milking goats, assisting with kidding, handling placentas, shovelling manure, having direct contact with goats, eating cheese made from goat milk, petting goats, feeding goats, being a worker, smoking tobacco, and drinking alcohol. When only a multivariate analysis was used, the following were significant risk factors for infection with *C. burnetii*: contact with the placenta ($P < 0.001$), smoking history ($P = 0.001$), and eating cheese made from [pasteurized] goat milk ($P = 0.022$). Consumption of goat milk itself was not associated with an increased risk of infection (OR 1.07) [30].

The authors concluded: 'The reason for the association between ingesting goat cheese and developing Q fever is not clear and suggests further study is needed. At present, this is an epidemiological association only, as *C. burnetii* has not been recovered from the goat cheese.'

There is also evidence from Australia that indicates direct contact (inhalation) with *C. burnetii* is more important in causing Q fever than other exposure including ingestion, as detected by immunological reactivity. Q fever has been a notifiable disease in Australia since 1977 with about 600 cases reported each year (range 202–870) [64, 65]. The majority of notified cases (60%) are from people employed in the meat industry as abattoir workers. About 30% of notified cases of Q fever are from the agricultural industry [64]. This would represent a Q fever

notification rate of 1240/100 000 and 164/100 000 for meat and agricultural sectors respectively. In contrast, immunological reactivity is more commonly found in the agricultural rather than the meat industry.

In Australia, immunological testing of people presenting for Q fever vaccination programmes for people at risk of infection in meat works or rural communities shows that prior to vaccination 17% of meat industry workers compared to 28% from the agricultural industries (including farm families) had positive reactions indicating previous exposure to *C. burnetii* [65]. All cows' milk sold in Australia must be pasteurized in accordance with Food Standards regulations and non-pasteurized milk is only available to farming families. It is also of interest to note that 85% of notified cases of Q fever in Australia are males and 70% of cases are between 20 and 50 years [65]. This pattern of disease is different from potential exposure through consumption of non-pasteurized milk.

Some authors accepting the foodborne transmission paradigm assumed that the form of the disease could be different according to the route of contamination: hepatitis for ingestion, pneumonia for inhalation [18, 28, 58, 66–70]. It is now recognized that this is not true [71].

CONCLUSION

From what is reported above, it seems more than plausible that clinical disease of Q fever results only from inhalation of *C. burnetii* and sometimes arthropods bites. Ingestion of *C. burnetii*-contaminated milk or milk products may result in serological conversion potentially indicating infection but not necessarily clinical disease. In addition it is likely that seroconversion follows the ingestion of inactivated cells as well as of live cells. Therefore, one may question:

- (1) Should Q fever be still listed among the foodborne zoonoses?
- (2) Should temperature and time conditions for milk pasteurization still be based on the heat resistance of *C. burnetii*?

If the answer is 'no' to both questions, the historical decision to pasteurize milk in order to kill *C. burnetii*, made almost 50 years ago, could be considered retrospectively as an early example of the application of the precautionary principle.

ACKNOWLEDGEMENTS

We acknowledge collaboration with A. Mimouni. Part of this work is a contribution by one of us (O.C.) to a report to the French Food Safety Agency (AFSSA).

DECLARATION OF INTEREST

None.

REFERENCES

1. **Anon.** Code of Hygienic Practice for Milk and Milk Products. Washington DC, USA, 29 March–2 April 2004: Joint FAO/WHO Food Standards Programme – Codex Committee on Food Hygiene, 26th Session, 2004.
2. **Marrie T, Raoult D.** Q fever – a review and issues for the next century. *International Journal of Antimicrobial Agents* 1997; **8**: 145–161.
3. **Wegener KH.** Q Fever and its signification regarding milk hygiene. Bibliographic study with contribution to the question of its occurrence in cattle herds in Schleswig-Holstein [in German]. *Kieler Milchwirtschaftliche Forschungsberichte* 1957; **9**: 509–535.
4. **Marmion B, Stoker G.** The epidemiology of Q fever in Great Britain. *British Medical Journal* 1958; **2**: 809–816.
5. **Huebner RJ, et al.** Q fever studies in southern California: III. Effects of pasteurization on survival of *C. burnetii* in naturally infected milk. *Public Health Report* 1949; **64**: 499–511.
6. **Kirberger E.** *In vitro* resistance of *Coxiella burnetii* [in German]. *Zeitschrift für Tropenmedizin und Parasitologie* 1951; **3**: 77–86.
7. **Bingel K, Engelhardt H.** Are our pasteurization processes sufficient to make innocuous the pathogen of Q fever in cow milk? [in German]. *Archiv für Hygiene* 1952; **136**: 417–425.
8. **Marmion B, et al.** The effect of pasteurization on milk containing *Rickettsia burneti*. *Monthly Bulletin of the Ministry of Health and the Public Health Laboratory Service* 1951; **10**: 119–128.
9. **Lennette EH, et al.** Q fever studies XIII. The effect of pasteurization on *Coxiella burnetii* in naturally infected milk. *American Journal of Hygiene* 1952; **55**: 246–253.
10. **Anon.** Q fever and milk pasteurization. *Public Health Report* 1957; **2**: 947–948.
11. **Enright JB, Sadler WW, Thomas RC.** Pasteurization of milk containing the organism of Q fever. *American Journal of Public Health* 1957; **47**: 695–700.
12. **Enright JB, Sadler WW, Thomas RC.** Thermal inactivation of *Coxiella burnetii* and its relation to pasteurization of milk, Public Health Monograph No. 47. PHS Publication No. 517. Washington, DC: U.S. Government Printing Office, 1957.

13. **Staal P.** Introduction. In: Cerf O, ed. *Bulletin of the International Dairy Federation, Bulletin 200/1986*. Brussels: International Dairy Federation, 1986.
14. **Cerf O.** Theory of microorganisms inactivation [in French]. In: Federighi M, Tholozan J-L, eds. *Traitements ionisants et hautes pressions des aliments*. Paris, France: Polytechnica, 2001.
15. **Acha PN, Szyfres B.** Zoonoses and communicable diseases common to man and animals [in French]. Paris: Office international des épizooties, 1989.
16. **Jorm LR, Lightfoot NF, Morgan KL.** An epidemiological study of an outbreak of Q fever in a secondary school. *Epidemiology and Infection* 1990; **104**: 467–477.
17. **Connolly JH, et al.** Clinical Q fever in Northern Ireland 1962–1989. *Ulster Medical Journal* 1990; **59**: 137–144.
18. **Fishbein DB, Raoult D.** A cluster of *Coxiella burnetii* infections associated with exposure to vaccinated goats and their unpasteurized dairy products. *American Journal of Tropical Medicine and Hygiene* 1992; **47**: 35–40.
19. **Brouqui P, et al.** Chronic Q fever. Ninety-two cases from France, including 27 cases without endocarditis. *Archives of Internal Medicine* 1993; **153**: 642–648.
20. **Thomas DR, et al.** The risk of acquiring Q fever on farms: a seroepidemiological study. *Occupational and Environmental Medicine* 1995; **52**: 644–647.
21. **Manfredi Selvaggi T, et al.** Investigation of a Q fever outbreak in Northern Italy. *European Journal of Epidemiology* 1996; **12**: 403–408.
22. **Pebody RG, et al.** Epidemiological features of *Coxiella burnetii* infection in England and Wales: 1984–1994. *Communicable Clinical Disease Report* 1996; **6**: R128–R132.
23. **Armengaud A, et al.** Urban outbreak of Q fever, Briançon, France, March to June 1996 [in French]. *Eurosurveillance* 1997; **2**: 12–13.
24. **Lyytikäinen O, et al.** Outbreak of Q fever in Lohra-Rollshausen, Germany, spring 1996 [in German]. *Eurosurveillance* 1997; **2**: 9–11.
25. **Serbežov V, et al.** Q fever in Bulgaria and Slovakia. *Emerging Infectious Clinical Diseases* 1999; **5**: 388–394.
26. **Tissot-Dupont H, et al.** Hyperendemic focus of Q fever related to sheep and wind. *American Journal of Epidemiology* 1999; **150**: 67–74.
27. **Baret M, et al.** *Coxiella burnetii* pneumopathy on return from French Guiana [in French]. *Bulletin de la Société de Pathologie Exotique* 2000; **93**: 325–327.
28. **Norlander L.** Q fever epidemiology and pathogenesis. *Microbes and Infection* 2000; **2**: 417–424.
29. **Petersen LR, et al.** Developing national epidemiological capacity to meet the challenges of emerging infections in Germany. *Emerging Infectious Clinical Diseases* 2000; **6**: 576–584.
30. **Hatchette TF, et al.** Goat-associated Q fever: a new clinical disease in Newfoundland. *Emerging Infectious Clinical Diseases* 2001; **7**: 413–419.
31. **Hellenbrand W, Breuer T, Petersen L.** Changing epidemiology of Q fever in Germany, 1947–1999. *Emerging Infectious Clinical Diseases* 2001; **7**: 789–796.
32. **Nebreda T, et al.** Outbreak of Q fever and seroprevalence in a rural population from Soria Province [in Spanish]. *Enfermedades Infecciosas y Microbiología Clínica* 2001; **19**: 57–60.
33. **Rousset E, et al.** Modalities of Q fever transmission to man [in French]. *Bulletin épidémiologique, AFSSA* 2003; **2003**: 1–4.
34. **Vincent C, Desjardins F.** Q fever [in French] Bulletin zoosanitaire. *Épidémiosurveillance Animale* 2001; **29**: 1–4.
35. **Anon.** Q fever [in German]. *Epidemiologisches Bulletin, Robert Koch Institut* 2002; **37**: 313–317.
36. **de Benoist A-C, et al.** Q fever outbreak in the Chamonix Valley, France, summer 2002 [Communiqués de presse]. Saint-Maurice: Institut National de Veille Sanitaire, 2002.
37. **Anon.** Factsheet: Q fever. *New South Wales Public Health Bulletin* 2002; **13**: 191.
38. **Carrieri M, et al.** Investigation of a slaughterhouse-related outbreak of Q fever in the French Alps. *European Journal of Clinical Microbiology and Infectious Clinical Diseases* 2002; **21**: 17–21.
39. **Benoist A-Cd, Mailles A, Denetiere G.** Q fever outbreak in the Chamonix Valley, France, summer 2002. *Eurosurveillance Weekly* 2002; **6**.
40. **Cekanac R, Lukac V, Coveljic M.** An epidemic of Q fever in a unit of the Yugoslav Army during war conditions [in Serbian]. *Vojnosanit Pregl* 2002; **59**: 157–160.
41. **Kotton C.** MedlinePlus Medical Encyclopedia – Q Fever; 2002 (<http://www.nlm.nih.gov/medlineplus/ency/article/001337.htm#Causes,%20incidence,%20and%20risk%20factors>). Accessed 31 Jan. 2006.
42. **Maltezou H, Raoult D.** Q fever in children. *Lancet Infectious Clinical Diseases* 2002; **2**: 686–691.
43. **Stiles ME.** Less recognized or presumptive foodborne pathogenic bacteria. In: Doyle MP, ed. *Foodborne Bacterial Pathogens*. Weimar, Texas: Culinary and Hospitality Industry Publications Services, 2002.
44. **Anon.** Q fever. Viral and Rickettsial Zoonoses Branch, Center for Clinical Disease Control and Prevention, Atlanta, GA (<http://www.cdc.gov/ncidod/dvrd/qfever/>), 2003. Accessed 31 Jan. 2006.
45. **Anon.** Q fever, 2003 (<http://www.vetmed.wisc.edu/pbs/zoonoses/Q%20fever/qfvrindx.html>). Accessed 31 Jan. 2006.
46. **Anon.** Fièvre Q. Polycopiés de maladies contagieuses des Écoles vétérinaires françaises (2002–2003), 2003 (<http://www.vet-alfort.fr/>). Accessed 31 Jan. 2006.
47. **Rey S, et al.** Investigation on a community outbreak of Q fever. Montoisson (Drôme) [in French]. Saint-Maurice: Institut National de Veille Sanitaire, p. 44; 2003.
48. **Rousset E, et al.** Epidemiology of animal Q fever. Situation in France [in French]. *Médecine des Maladies Infectieuses* 2001; **31** (Suppl. 2): 233–246.
49. **Weise E.** *Q-Fieber*. Bonn (Deutschland): Bundesinstitut für Risikobewertung, 2003.
50. **Anon.** Medical NBC Online Information Server, 2003.
51. **McQuiston J, Childs J.** Q fever in humans and animals in the United States. *Vector Borne Zoonotic Disease* 2002; **2**: 179–191.

52. **Anon.** Establishment of Specifications and Standards Based on the Food Sanitation Law – 2002. FFCR –The Japan Food Chemical Research Foundation, Information on Food Safety in Japan, Ministry of Health, Labour and Welfare, 2002.
53. **Mak D, Fry D, Bulsara M.** Prevalence of markers of Q fever exposure in the Kimberley, Western Australia. *Communicable Clinical Diseases Intelligence* 2003; **27**: 267–271.
54. **Santoro D, et al.** Q fever in Como, Northern Italy. *Emerging Infectious Clinical Diseases* 2004; **10** (<http://www.cdc.gov/ncidod/EID/vol10no1/03-0467.htm>). Accessed 1 Feb. 2006.
55. **Smith R.** Occupational exposure risk for Q fever and other zoonoses among those working on control of the foot and mouth clinical disease epidemic in the United Kingdom. *Eurosurveillance Weekly* 2001; **7** (<http://www.eurosurveillance.org/ew/2001/010705.asp#1>). Accessed 31 Jan. 2006.
56. **Brown G, Colwell D, Hooper W.** An outbreak of Q fever in Staffordshire. *Journal of Hygiene (Cambridge)* 1968; **66**: 649–655.
57. **Hahn G, Koch P.** *Coxiella burnetii*. Monograph on the significance of pathogenic microorganisms in raw milk. Special Issue No. 9405. Brussels, Belgium: IDF Group of Experts AIO/A11. International Dairy Federation, 1993.
58. **Tissot-Dupont H, Raoult D.** Epidemiology of Q fever [in French]. *Bulletin Épidémiologique Hebdomadaire* 1993; **1993**: 17–18.
59. **Tselentis Y, et al.** Q fever in the Greek Island of Crete: epidemiologic, clinical, and therapeutic data from 98 cases. *Clinical Infectious Diseases* 1995; **20**: 1311–1316.
60. **Suarez-Estrada J, et al.** Seroepidemiological survey of Q fever in Leon Province, Spain. *European Journal of Epidemiology* 1996; **12**: 245–250.
61. **Combiesco D.** Pulmonary typhus fever – pulmonary rickettsiosis [in French]. *Archives Roumaines des Pathologies Expérimentales et de Microbiologie* 1957; **16**: 37–55.
62. **Benson WW, Brock DW, Mather J.** Serologic analysis of a penitentiary group using raw milk from a Q fever infected herd. *Public Health Report* 1963; **78**: 707–710.
63. **Durand MP, Limouzin C.** A food hygiene problem: a propos the potential risk on human health of cow milk infected by *Coxiella burnetii* [in French]. *Bulletin de l'Académie Vétérinaire de France* 1983; **56**: 475–485.
64. **Garner MG, et al.** A review of Q fever in Australia 1991–1994. *Australia and New Zealand Journal of Public Health* 1997; **21**: 722–730.
65. **Kermode M, et al.** An economic evaluation of increased uptake in Q fever vaccination among meat and agricultural industry workers following implementation of the National Fever Management Program. *Australia and New Zealand Journal of Public Health* 2003; **27**: 390.
66. **La Scola B, Lepidi H, Raoult D.** Pathologic changes during acute Q fever: influence of the route of infection and inoculum size in infected guinea pigs. *Infection and Immunity* 1997; **65**: 2443–2447.
67. **de Alarcon A, et al.** Q fever: epidemiology, clinical features and prognosis. A study from 1983 to 1999 in the South of Spain. *Journal of Infection* 2003; **47**: 110–116.
68. **Tiggert WD, Benenson AS.** Studies on Q fever in man. *Transactions of the Association of American Physicians* 1956; **69**: 98–104.
69. **Marrie T, et al.** Exposure to parturient cats is a risk factor for acquisition of Q fever in Maritime Canada. *Journal of Infectious Clinical Diseases* 1988; **319**: 354–356.
70. **Domingo P, et al.** Acute Q fever in adult patients: report on 63 sporadic cases in an urban area. *Clinical Infectious Diseases* 1999; **29**: 874–879.
71. **Raoult D, et al.** Q fever 1985–1998. Clinical and epidemiologic features of 1,383 infections. *Medicine* 2000; **79**: 109–123.